Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma

NCT02234115 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

137

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: Leuprolide Mesylate

Sponsor

Foresee Pharmaceuticals Co., Ltd.